GlassScriptPhysician profile
Bindu Sehgal
NPI 1770550824
$3,725.68
in general payments reported to CMS, 2019-2025
34 companies · $648 in 2025
The $648 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $535 · 2021: $795 · 2022: $458 · 2023: $224 · 2024: $640 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $478.07 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Teva Pharmaceuticals USA, INC. | $423.64 | 2019-2023 | Ajovy, Airduo Digihaler |
| Abbvie INC. | $369.83 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $335.20 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Lilly USA, LLC | $203.17 | 2019-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $200.26 | 2019-2025 | |
| Glaxosmithkline, LLC. | $173.58 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Novo Nordisk INC | $171.93 | 2019-2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $140.90 | 2019-2022 | |
| Sanofi Pasteur INC. | $124.30 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $108.10 | 2021-2023 | Spravato |
| Amgen INC. | $103.42 | 2019-2025 | Repatha |
| Exact Sciences Corporation | $80.43 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $78.31 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.66 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $69.87 | 2022-2025 | Nexplanon |
| E.R. Squibb & Sons, L.L.C. | $66.59 | 2021-2025 | Camzyos, Eliquis |
| Painteq LLC | $56.19 | 2023 | Painteq |
| Shire North American Group INC | $53.85 | 2019 | |
| Eisai INC. | $43.32 | 2020 | |
| Novartis Pharmaceuticals Corporation | $41.40 | 2022 | |
| Supernus Pharmaceuticals, INC. | $38.30 | 2021-2022 | |
| Esperion Therapeutics, INC. | $37.20 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $36.62 | 2019-2020 | |
| Astellas Pharma US INC | $33.80 | 2019-2020 | |
| Organogenesis INC. | $31.35 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $30.03 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.41 | 2022 | |
| Allergan, INC. | $23.53 | 2020 | |
| Xeris Pharmaceuticals, INC. | $18.30 | 2024 | Gvoke Hypopen |
| Ultragenyx Pharmaceutical INC. | $15.58 | 2021 | |
| Hologic Sales and Service, LLC | $14.67 | 2019 | |
| Amarin Pharma, INC. | $13.39 | 2021 | |
| Hikma Pharmaceuticals USA | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindu Sehgal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.